BMRN (STOCKS)
BioMarin Pharmaceuticals Inc
$54.880000
+0.350000 (+0.64%)
Prev close: $54.530000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Alexander Hardy
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $10,556.63M
- Employees
- 3,040
- P/E (TTM)
- 30.22
- P/B (TTM)
- 1.72
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
10
Strong Buy
15
Buy
6
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.24 | $0.64 | -0.8770 | -137.68% |
|
Sep 2025 (Q3)
|
$-0.16 | $0.38 | -0.5393 | -142.18% |
|
Jun 2025 (Q2)
|
$1.23 | $0.85 | +0.3784 | +44.43% |
|
Mar 2025 (Q1)
|
$0.95 | $0.72 | +0.2274 | +31.47% |
Financial Statements
| Revenues | $3.22B |
| Benefits Costs and Expenses | $2.74B |
| Cost Of Revenue | $717.44M |
| Costs And Expenses | $2.81B |
| Gross Profit | $2.50B |
| Operating Expenses | $2.09B |
| Selling, General, and Administrative Expenses | $1.15B |
| Research and Development | $921.93M |
| Other Operating Expenses | $19.39M |
| Operating Income/Loss | $409.48M |
| Income/Loss From Continuing Operations After Tax | $348.90M |
| Income/Loss From Continuing Operations Before Tax | $482.48M |
| Income Tax Expense/Benefit | $133.58M |
| Income Tax Expense/Benefit, Current | $84.84M |
| Income Tax Expense/Benefit, Deferred | $48.74M |
| Net Income/Loss | $348.90M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $348.90M |
| Net Income/Loss Available To Common Stockholders, Basic | $348.90M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $1.82 |
| Diluted Earnings Per Share | $1.80 |
| Basic Average Shares | 191,787,000 |
| Diluted Average Shares | 197,394,000 |
| Assets | $7.59B |
| Current Assets | $3.95B |
| Inventory | $1.30B |
| Other Current Assets | $2.65B |
| Noncurrent Assets | $3.64B |
| Fixed Assets | $952.51M |
| Intangible Assets | $213.84M |
| Other Non-current Assets | $2.47B |
| Liabilities | $1.51B |
| Current Liabilities | $759.03M |
| Wages | $219.42M |
| Other Current Liabilities | $539.61M |
| Noncurrent Liabilities | $747.99M |
| Equity | $6.09B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $6.09B |
| Liabilities And Equity | $7.59B |
| Net Cash Flow From Operating Activities | $827.99M |
| Net Cash Flow From Operating Activities, Continuing | $827.99M |
| Net Cash Flow From Investing Activities | -$414.24M |
| Net Cash Flow From Investing Activities, Continuing | -$414.24M |
| Net Cash Flow From Financing Activities | -$42.39M |
| Net Cash Flow From Financing Activities, Continuing | -$42.39M |
| Net Cash Flow | $371.36M |
| Net Cash Flow, Continuing | $371.36M |
| Comprehensive Income/Loss | $273.78M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $273.78M |
| Other Comprehensive Income/Loss | $273.78M |
| Other Comprehensive Income/Loss Attributable To Parent | -$75.13M |